LINC00294 negatively modulates cell proliferation in glioma through a neurofilament medium-mediated pathway via interacting with miR-1278.

BACKGROUND: Accumulating long noncoding RNAs (lncRNAs) have been recognized to participate in glioma development. Nevertheless, knowledge of the role of linc00294 in glioma remains incomplete. METHODS: Bioinformatics analysis predicted the differential expression of LINC00294 and neurofilament medium (NEFM) in tumors and normal tissues, as well as the binding between LINC00294 and miR-1278, miR-1278 and NEFM. Luciferase and RNA immunoprecipitation assays were used for the verification of interactions. The potential role of LINC00294 in glioma development was investigated using functional assays, singly and in parallel with its interplay with miR-1278 and NEFM. Cell counting kit-8 and EdU assays were applied to measure cellular proliferation, whereas the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method was employed to detect apoptosis. RESULTS: A new lncRNA, LINC00294, was highly expressed in normal brain tissues. However, it was markedly down-regulated in GBM tissues and glioma cell lines. Overexpression of LINC00294 abates glioma cell proliferation but induces apoptosis. Meanwhile, tumor suppressor NEFM was revealed to be distinctly diminished in cancerous conditions and enhanced in glioma cells by LINC00294 up-regulation. Interactions of miR-1278 with LINC00294 or NEFM occur, and the expression of NEFM is up-regulated by LINC00294 through their competition with respect to binding to miR-1278. Finally, the rescue assays further confirmed that LINC00294 inhibits glioma cell proliferation by absorbing miR-1278 to enhance NEFM. CONCLUSIONS: Collectively, our observations demonstrate the tumor-suppressive function of LINC00294 in glioma development by sponging miR-1278 and promoting NEFM, suggesting a potential use in therapy for glioma.

Ultrafast Electrical Pulse Synthesis of Highly Active Electrocatalysts for Beyond-Industrial-Level Hydrogen Gas Batteries.

The high reliability and proven ultra-longevity make aqueous hydrogen gas (H2 ) batteries ideal for large-scale energy storage. However, the low alkaline hydrogen evolution and oxidation reaction (HER/HOR) activities of expensive platinum catalysts severely hamper their widespread applications in H2 batteries. Here, cost-effective, highly active electrocatalysts, with a model of ruthenium-nickel alloy nanoparticles in ≈3 nm anchored on carbon black (RuNi/C) as an example, are developed by an ultrafast electrical pulse approach for nickel-hydrogen gas (NiH2 ) batteries. Having a competitive low cost of about one fifth of Pt/C benckmark, this ultrafine RuNi/C catalyst displays an ultrahigh HOR mass activity of 2.34 A mg-1 at 50 mV (vs RHE) and an ultralow HER overpotential of 19.5 mV at a current density of 10 mA cm-2 . As a result, the advanced NiH2 battery can efficiently operate under all-climate conditions (from -25 to +50 °C) with excellent durability. Notably, the NiH2 cell stack achieves an energy density up to 183 Wh kg-1 and an estimated cost of ≈49 $ kWh-1 under an ultrahigh cathode Ni(OH)2 loading of 280 mg cm-2 and a low anode Ru loading of ≈62.5 µg cm-2 . The advanced beyond-industrial-level hydrogen gas batteries provide great opportunities for practical grid-scale energy storage applications.

Solid-Liquid-Gas Management for Low-Cost Hydrogen Gas Batteries.

Aqueous nickel-hydrogen gas (Ni-H2) batteries with excellent durability (>10,000 cycles) are important candidates for grid-scale energy storage but are hampered by the high-cost Pt electrode with limited performance. Herein, we report a low-cost nickel-molybdenum (NiMo) alloy as an efficient bifunctional hydrogen evolution and oxidation reaction (HER/HOR) catalyst for Ni-H2 batteries in alkaline electrolytes. The NiMo alloy demonstrates a high HOR mass-specific kinetic current of 28.8 mA mg-1 at 50 mV as well as a low HER overpotential of 45 mV at a current density of 10 mA cm-2, which is better than most nonprecious metal catalysts. Furthermore, we apply a solid-liquid-gas management strategy to constitute a conductive, hydrophobic network of NiMo using multiwalled carbon nanotubes (NiMo-hydrophobic MWCNT) in the electrode to accelerate HER/HOR activities for much improved Ni-H2 battery performance. As a result, Ni-H2 cells based on the NiMo-hydrophobic MWCNT electrode show a high energy density of 118 Wh kg-1 and a low cost of only 67.5 $ kWh-1. With the low cost, high energy density, excellent durability, and improved energy efficiency, the Ni-H2 cells show great potential for practical grid-scale energy storage.

Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).

OBJECTIVE: This work was designed to explore whether the combination of Tanshinone IIA (T-IIA) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has a direct anti-cancer effect in glioblastoma (GBM) and the possible mechanisms. METHODS: GBM cells (U-87 and U-251 MG) were treated with T-IIA or/and TRAIL, or the expression of death receptors (DRs), DR4 and DR5, was suppressed in GBM cells. The activity of GBM cells was determined by MTT, and the apoptosis was assessed by Hoechst33342 staining and flow cytometry. The expression levels of cleaved caspase-3/8/9, phosphorylated (p)-STAT3 as well as DR4 and DR5 in GBM cells were assessed by Western blotting. A nude mouse xenograft model was constructed to evaluate the effects of T-IIA and TRAIL cotreatment on tumor growth and apoptosis in vivo. RESULTS: After T-IIA treatment, GBM cells resumed the sensitivity to TRAIL-induced apoptosis dependent on inhibition of p-STAT3 and activation of DR4, DR5 and caspases. DR4 or/and DR5 knockdown significantly abated the co-effect of T-IIA and TRAIL on GBM cell apoptosis and proliferation. Furthermore, T-IIA and TRAIL cotreatment markedly inhibited the growth of transplanted tumor and activated U87 cell apoptosis in nude mice. CONCLUSION: T-IIA increases TRAIL-induced apoptosis by downregulating STAT3 and upregulating DR4 and DR5, indicating T-IIA therapy as a novel treatment strategy for TRAIL-resistant GBM.